T2's COVID-19 molecular test gets FDA nod

By LabPulse.com staff writers

September 2, 2020 -- The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization to T2 Biosystems for its COVID-19 molecular diagnostic test, T2SARS-CoV-2 Panel.

The assay tests for the SARS-CoV-2 virus using nasopharyngeal swab samples and provides results in less than two hours. The panel runs on the company's FDA-cleared and automated T2Dx instrument, which can perform seven tests simultaneously. It demonstrated a sensitivity of 95% and specificity of 100% on both positive and negative patient samples, according to the company.


Copyright © 2020 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?